Jiamin Sheng
Chinese Academy of Sciences
CorrelationMutation (genetic algorithm)Copy-number variationInternal medicineOncologyImmunohistochemistryLung cancerChemotherapyPerformance statusCombination therapyVascular endothelial growth factorOsimertinibImmunotherapyT790Mnon-small cell lung cancer (NSCLC)CrizotinibEpidermal growth factor receptorCDKN2AKRASEGFR T790MNon small cellMet amplificationCancer researchMedicineCohortAbundance (ecology)
4Publications
1H-index
2Citations
Publications 4
Newest
#1Xiaoqing Yu (CAS: Chinese Academy of Sciences)H-Index: 2
#2Jiamin Sheng (CAS: Chinese Academy of Sciences)H-Index: 1
Last. Yun Fan (CAS: Chinese Academy of Sciences)H-Index: 3
view all 4 authors...
Brain metastases (BMs) cause morbidity and mortality in patients with non-small cell lung cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR)-mutated NSCLC with BM is debatable. We aimed to investigate the impact of different treatments among patients with EGFR-mutated NSCLC. A cohort of 2058 lung cancer patients with BM between 2013 and 2018 was retrospectively studied. A total of 571 patients with EGFR-mutated NSCLC and BM were enrolled. All patients had received ...
Source
Source
#1Kaiyan Chen (CAS: Chinese Academy of Sciences)H-Index: 11
#2Fanrong Zhang (CAS: Chinese Academy of Sciences)H-Index: 8
Last. Yun Fan (CAS: Chinese Academy of Sciences)H-Index: 2
view all 9 authors...
Source
#1Yanjun Xu (CAS: Chinese Academy of Sciences)H-Index: 7
#2Hui LiH-Index: 1
Last. Yun Fan (WMU: Wenzhou Medical College)H-Index: 4
view all 8 authors...
Background Immune checkpoint inhibitors (ICIs) prolong overall survival (OS) in patients with advanced lung squamous cell carcinoma (LUSC). However, predictive and prognostic factors related to ICIs in LUSC remain elusive. This study aimed to identify predictors that are related to better clinical benefit and outcomes in LUSC patients treated with immunotherapy. Methods Capture-based targeted sequencing was performed in 64 patients with advanced LUSC who underwent immunotherapy. Tumor mutational...
5 CitationsSource